GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Shiller PE Ratio

Supernus Pharmaceuticals (FRA:S49) Shiller PE Ratio : 23.09 (As of May. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Supernus Pharmaceuticals Shiller PE Ratio?

As of today (2024-05-01), Supernus Pharmaceuticals's current share price is €28.40. Supernus Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was €1.23. Supernus Pharmaceuticals's Shiller PE Ratio for today is 23.09.

The historical rank and industry rank for Supernus Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

FRA:S49' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.55   Med: 39.11   Max: 79.92
Current: 22.24

During the past years, Supernus Pharmaceuticals's highest Shiller PE Ratio was 79.92. The lowest was 18.55. And the median was 39.11.

FRA:S49's Shiller PE Ratio is ranked better than
55.35% of 533 companies
in the Drug Manufacturers industry
Industry Median: 24.9 vs FRA:S49: 22.24

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was €0.016. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €1.23 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Supernus Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Supernus Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Shiller PE Ratio Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 55.15 38.05 21.39

Supernus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.05 34.17 25.35 21.71 21.39

Competitive Comparison of Supernus Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Shiller PE Ratio falls into.



Supernus Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Supernus Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=28.40/1.23
=23.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Supernus Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.016/129.4194*129.4194
=0.016

Current CPI (Dec. 2023) = 129.4194.

Supernus Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.275 99.695 -0.357
201406 0.059 100.560 0.076
201409 -0.047 100.428 -0.061
201412 0.081 99.070 0.106
201503 0.018 99.621 0.023
201506 0.036 100.684 0.046
201509 0.071 100.392 0.092
201512 0.129 99.792 0.167
201603 0.072 100.470 0.093
201606 0.160 101.688 0.204
201609 1.051 101.861 1.335
201612 0.246 101.863 0.313
201703 0.178 102.862 0.224
201706 0.285 103.349 0.357
201709 0.243 104.136 0.302
201712 0.220 104.011 0.274
201803 0.397 105.290 0.488
201806 0.488 106.317 0.594
201809 0.446 106.507 0.542
201812 0.422 105.998 0.515
201903 0.301 107.251 0.363
201906 0.540 108.070 0.647
201909 0.490 108.329 0.585
201912 0.558 108.420 0.666
202003 0.362 108.902 0.430
202006 0.577 108.767 0.687
202009 0.628 109.815 0.740
202012 0.469 109.897 0.552
202103 0.092 111.754 0.107
202106 0.357 114.631 0.403
202109 0.340 115.734 0.380
202112 0.035 117.630 0.039
202203 0.390 121.301 0.416
202206 0.132 125.017 0.137
202209 0.030 125.227 0.031
202212 0.406 125.222 0.420
202303 0.271 127.348 0.275
202306 -0.018 128.729 -0.018
202309 -0.272 129.860 -0.271
202312 0.016 129.419 0.016

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Supernus Pharmaceuticals  (FRA:S49) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Supernus Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (FRA:S49) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (FRA:S49) Headlines

No Headlines